Wanbangde Pharmaceutical Holding Group Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 0.24%

Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has an Asset Resilience Ratio of 0.24% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Wanbangde Pharmaceutical Holding Group C (002082) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥10.41 Million
≈ $1.52 Million USD Cash + Short-term Investments

Total Assets

CN¥4.43 Billion
≈ $647.96 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2004–2024)

This chart shows how Wanbangde Pharmaceutical Holding Group Co Ltd's Asset Resilience Ratio has changed over time. See Wanbangde Pharmaceutical Holding Group C net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Wanbangde Pharmaceutical Holding Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Wanbangde Pharmaceutical Holding Group C market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥10.41 Million 0.24%
Total Liquid Assets CN¥10.41 Million 0.24%

Asset Resilience Insights

  • Limited Liquidity: Wanbangde Pharmaceutical Holding Group Co Ltd maintains only 0.24% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Wanbangde Pharmaceutical Holding Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wanbangde Pharmaceutical Holding Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Wanbangde Pharmaceutical Holding Group Co Ltd (2004–2024)

The table below shows the annual Asset Resilience Ratio data for Wanbangde Pharmaceutical Holding Group Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.26% CN¥11.15 Million
≈ $1.63 Million
CN¥4.33 Billion
≈ $633.23 Million
-1.74pp
2014-12-31 2.00% CN¥31.00 Million
≈ $4.54 Million
CN¥1.55 Billion
≈ $226.96 Million
+1.92pp
2005-12-31 0.07% CN¥491.18K
≈ $71.88K
CN¥661.73 Million
≈ $96.83 Million
-0.05pp
2004-12-31 0.12% CN¥517.57K
≈ $75.74K
CN¥416.66 Million
≈ $60.97 Million
--
pp = percentage points

About Wanbangde Pharmaceutical Holding Group Co Ltd

SHE:002082 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.22 Billion
CN¥8.35 Billion CNY
Market Cap Rank
#8212 Global
#1988 in China
Share Price
CN¥13.65
Change (1 day)
-0.22%
52-Week Range
CN¥6.60 - CN¥36.24
All Time High
CN¥36.24
About

Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascul… Read more